aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced that Sanjay S. Shukla,
M.D., M.S., President and Chief Executive Officer, will present a
corporate overview at the H.C. Wainwright Virtual BioConnect
Conference, which is being held from January 11-14, 2021.
The presentation will be available for on-demand
access starting Monday, January 11, 2021, at 6:00am ET. A copy of
the presentation will be available on the Investor’s section of the
Company’s website at www.atyrpharma.com and will be available for
90 days following the event.
Company management will also participate in
virtual one-on-one meetings with registered attendees of the
partnering system hosted by the Biotechnology Innovation
Organization (BIO) during the J.P. Morgan Healthcare Conference
week from January 11-15, 2021. For more information, please visit
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
Investor Relations and Corporate